A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Polidocanol Injectable Foam 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence.
Latest Information Update: 22 Apr 2021
At a glance
- Drugs Polidocanol (Primary)
- Indications Varicose veins
- Focus Registrational; Therapeutic Use
- Acronyms VANISH-1
- Sponsors BTG; BTG International
- 04 Mar 2014 New trial record